What the MHRA has actually approved

Authorisation means the MHRA has assessed orforglipron’s safety, quality and effectiveness and concluded it can be licensed for use in the UK. Julian Beach, the MHRA’s Executive Director for healthcare quality and access, described it as following “rigorous assessment”, and confirmed the regulator “will keep the safety and effectiveness of orforglipron under close review”.

Orforglipron has been authorised for two separate indications:

• Weight management — weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.
• Type 2 diabetes — improving blood glucose control in adults whose type 2 diabetes is insufficiently controlled, again alongside diet and exercise.

The dual indication matters. Most coverage of orforglipron has framed it purely as a weight-loss product, but its diabetes licence puts it alongside tirzepatide and semaglutide, which are also licensed for both.

What orforglipron is, and how it works

Orforglipron is a GLP-1 receptor agonist. GLP-1 is a hormone your body releases naturally after eating. It acts on areas of the brain that regulate appetite, increasing the feeling of fullness and reducing hunger and food cravings. In people with type 2 diabetes it also helps lower elevated blood glucose.

What sets orforglipron apart from the GLP-1 medicines already in use is its chemistry. Semaglutide and tirzepatide are peptides — large, fragile molecules that are difficult for the body to absorb from the gut, which is why they are normally injected. Orforglipron is a small-molecule, non-peptide drug designed from the outset to survive digestion. That is what allows it to work as a straightforward daily tablet.

The difference that is likely to matter most day to day

There is already an oral GLP-1 in the UK — oral semaglutide, authorised for weight loss in June 2026. But it comes with a demanding routine: it must be taken on an empty stomach after at least eight hours without food, swallowed whole with a small amount of water, and followed by a further 30-minute wait before eating, drinking or taking any other medicine. For a lot of people that is the hardest part of the treatment, and it is a common reason for missed doses.

The MHRA’s authorisation confirms orforglipron is taken once daily at any time of day, with no food or water restrictions. For anyone who has struggled with the fasting routine — or who simply cannot fit it around shift work, childcare or an early commute — that is a meaningful practical difference rather than a marketing one.

How it is dosed

Orforglipron is not started at full strength. Like other GLP-1 medicines it is introduced gradually, which gives the digestive system time to adjust and reduces the nausea that is common in the early weeks.

The MHRA has authorised six tablet strengths, and treatment steps up through them:

The MHRA specifies a minimum of one month at each dose level before moving up. Two things follow. First, reaching the highest dose takes at least five months, so this is not a short-term intervention. Second, not everyone goes all the way — the right dose is the one that works and is tolerated, and a prescriber may hold you at a lower step.

How well does it work?

Orforglipron was tested in two large phase 3 programmes: ATTAIN, in people with obesity or overweight, and ACHIEVE, in people with type 2 diabetes.

ATTAIN-1 followed 3,127 adults with obesity or overweight but without diabetes over 72 weeks. On the highest trial dose (36 mg of the investigational formulation), average weight loss was 12.4% versus 0.9% on placebo on the efficacy estimand — the analysis of people who took the medicine as directed. Counting everyone randomised, including those who stopped, the figures were 11.2% versus 2.1%. Around 60% of those on the highest trial dose lost at least 10% of their body weight, compared with 9% on placebo; about 40% lost at least 15%, compared with 4% on placebo. Improvements were also seen in waist circumference, blood pressure, triglycerides and cholesterol.

In ATTAIN-2, in people with both obesity and type 2 diabetes, average weight loss on the highest trial dose was 10.5% over 72 weeks on the efficacy estimand (9.6% counting everyone randomised), versus 2.2% on placebo, alongside a 1.8 percentage-point reduction in HbA1c.

In ACHIEVE-3 — the only head-to-head trial against another oral GLP-1 — orforglipron produced greater reductions in HbA1c and greater weight loss than oral semaglutide in people with type 2 diabetes. It also caused more digestive side effects, and roughly twice as many participants stopped treatment because of side effects.

Being honest about comparisons

You will see orforglipron’s 12.4% set against figures like 22.5% for tirzepatide and 14.9% for semaglutide. Those comparisons are not like-for-like. They come from different trials, run in different populations, over different lengths of time, and analysed using different statistical methods. No trial has directly compared orforglipron with injectable tirzepatide or semaglutide for weight loss.

What can reasonably be said is that orforglipron produced substantial, clinically meaningful weight loss in tablet form, and that the injectable options have — in their own trials — produced larger average figures. Whether a somewhat smaller average result in a tablet you can take at any time is a better fit than a larger one in a weekly injection is exactly the kind of judgement that belongs in a conversation with a prescriber, not in a headline.

Side effects

The UK label classes nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain as very common — each affecting more than one person in ten. This is broadly the pattern seen across the GLP-1 class, and these effects are generally most noticeable in the first weeks after starting and after each dose increase, easing as the body adjusts. The gradual dose escalation exists specifically to limit them.

In the trials, digestive side effects were the most common reason for stopping treatment. The UK label reports that 6.8% of people on the highest trial dose stopped because of digestive side effects, against 0.6% on placebo. Our side effects guide sets out the full UK frequency list.

Who should not take it, and other important warnings

The UK label lists one contraindication. Section 4.3 of the UK Summary of Product Characteristics reads, in full: hypersensitivity to orforglipron or to any of the tablet’s other ingredients. There is nothing else in it.

This is worth stating clearly, because it differs from the United States. The US prescribing information carries a boxed warning about thyroid C-cell tumours seen in rodent studies, and on that basis contraindicates the medicine in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The UK label does not. Thyroid tumours, medullary thyroid carcinoma and MEN 2 are not mentioned anywhere in the UK document, and there is no boxed warning. If you have read that this medicine is contraindicated in thyroid cancer, that is the US position, not the UK one. Differences of this kind between UK and US labelling are common across the GLP-1 class.

The UK label instead sets out a list of things a prescriber will weigh before prescribing, and monitor during treatment:

• Pregnancy and breastfeeding. Orforglipron should not be used in pregnancy, and should be stopped if you become pregnant or wish to. Because of how long it stays in the body, the UK label says it should be stopped at least three weeks before a planned pregnancy. It should not be used while breastfeeding, and effective contraception is needed during treatment.
• Oral contraceptives. This one is easy to miss and matters. Because orforglipron slows stomach emptying, oral contraceptive pills may not be reliably absorbed. Women using oral contraception are advised to switch to a non-oral method, or add a barrier method, for 30 days after starting orforglipron and for 30 days after every dose increase. With six dose levels, that is a repeated instruction, not a one-off.
• Pancreatitis. Acute pancreatitis has been reported with GLP-1 medicines. Severe, persistent abdominal pain needs urgent medical attention.
• Gallbladder problems. Gallstones and gallbladder inflammation have been reported.
• Low blood sugar. Orforglipron alone rarely causes hypoglycaemia, but the risk rises considerably when it is combined with insulin or a sulfonylurea. Those doses may need reducing.
• Severe digestive conditions. It is not recommended in severe gastroparesis, and it should be stopped or used cautiously where there is significant ongoing vomiting or dehydration, which can affect the kidneys.
• Liver problems. Not recommended in severe liver impairment. No dose change is needed for mild or moderate liver impairment.
• Kidneys. No dose change is needed for any level of kidney function, including dialysis. But vomiting and diarrhoea can cause dehydration, and dehydration can injure the kidneys — which is why keeping fluids up matters.
• Blood pressure. Orforglipron can lower blood pressure, and this was reported more often in people already taking blood-pressure medicines.
• Heart failure. There is no experience in severe (NYHA class IV) heart failure, and it is not recommended in that group.
• Previous pancreatitis. It has not been studied in people with a history of pancreatitis and should be used with caution in them.
• Surgery and sedation. Because it delays stomach emptying, tell any anaesthetist or surgical team that you are taking it before a planned procedure.
• Other GLP-1 medicines. It should not be taken alongside another GLP-1 medicine.

Interactions with other medicines

Orforglipron differs from the injectable GLP-1s in an important way. Because it is a small molecule rather than a peptide, it is handled by the body’s ordinary drug-processing machinery: the UK label describes it as a substrate of the liver enzymes CYP3A4 and CYP2J2, and of the transporters P-gp, OATP1B1 and OATP1B3. That gives it a set of interactions the injectable peptides simply do not have.

• Strong CYP3A4 inhibitors — ketoconazole, clarithromycin, itraconazole. Clarithromycin raised orforglipron exposure roughly three and a half times in a study, so the dose is capped at 9 mg while they are taken together.
• Strong CYP3A4 inducers — carbamazepine, for instance. These lower orforglipron levels and should be avoided.
• OATP1B inhibitors — a separate group, and easy to miss. The dose is also capped at 9 mg when one is taken alongside.
• Simvastatin. The UK label says the simvastatin dose should be halved when the two are taken together.
• Oral contraceptives — see the warning above.
• Insulin and sulfonylureas — doses may need reducing, because the risk of low blood sugar rises.

This is not a complete list. Anyone considering treatment should give a prescriber a full list of everything they take, including anything bought over the counter and any supplements.

Orforglipron and the NHS

The MHRA has been explicit: while orforglipron is now approved for use in the UK, it is not currently available through the NHS.

Authorisation and NHS funding are two separate decisions made by two separate bodies. The MHRA decides whether a medicine is safe and effective enough to be licensed. NICE then assesses whether it represents good value for the NHS. That appraisal is already under way, and NICE’s guidance is currently expected on 18 November 2026.

We set out the NICE timetable, what a positive decision would and would not mean, and when orforglipron is available in the UK and what it costs, on a separate page.

How access to orforglipron works in the UK

No UK launch date has been announced by Eli Lilly, and no UK price has been published. Anything you read giving a specific date or monthly cost is an estimate rather than confirmed information.

When it does launch, orforglipron will remain a prescription-only medicine. That means it can only be supplied by a registered pharmacy, against a prescription written by a prescriber who has assessed you individually. There is no legitimate route to obtain it without that assessment — and since launch on 24 August 2026 the only route is through a regulated UK pharmacy after that assessment.

Anyone currently offering to sell orforglipron, or to import it from the United States, is operating outside UK law. Medicines bought that way are not covered by UK safety regulation. The MHRA has repeatedly seized unlicensed weight-loss medicines from the illegal market, including two illicit manufacturing operations shut down in England during 2026.

What we still do not know

We would rather tell you what is uncertain than fill the gaps with guesswork. Two of the items previously listed here have now been answered: the UK Summary of Product Characteristics and patient information leaflet were published on 14 August 2026, and the medicine carries a black triangle (additional monitoring) rather than a boxed warning. As of 24 August 2026 the following are still genuinely not established:

• Whether initial UK supply will be limited (launch was 24 August 2026).
• The UK price, private or NHS.
• NICE’s decision, expected 18 November 2026.
• Real-world safety data at scale. Orforglipron was authorised days ago and is under additional monitoring precisely because that data does not exist yet.

We will update this page as each is confirmed, and note the date of every change at the foot of the page.